{"id":"urea-lactic-acid","safety":{"commonSideEffects":[{"rate":null,"effect":"Local irritation or burning sensation"},{"rate":null,"effect":"Erythema"},{"rate":null,"effect":"Pruritus"}]},"_chembl":{"chemblId":"CHEMBL1200559","moleculeType":"Small molecule","molecularWeight":"90.08"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Urea acts as a keratolytic agent that breaks down and softens hardened, thickened skin by disrupting hydrogen bonds in keratin, while lactic acid provides gentle chemical exfoliation and humectant properties. Together, they improve skin barrier function, increase moisture retention, and promote removal of dead skin cells, making this combination effective for hyperkeratotic and xerotic skin conditions.","oneSentence":"Urea and lactic acid work together to soften and exfoliate the stratum corneum while restoring skin hydration and pH balance.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:37:35.780Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hyperkeratosis and xerosis (dry, thickened skin)"},{"name":"Calluses and corns"},{"name":"Ichthyosis and related keratinization disorders"}]},"trialDetails":[{"nctId":"NCT06114498","phase":"","title":"Hospital Register of Decompensated Heart Failure With Preserved Ejection Fraction","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Medical Research Center for Therapy and Preventive Medicine","startDate":"2023-09-01","conditions":"Heart Failure With Preserved Ejection Fraction, Obesity, Mild, Decompensated Heart Failure","enrollment":240},{"nctId":"NCT04659876","phase":"","title":"Factors Affecting Mortality in Critical Patients Admitted to Intensive Care Unit Due to Coronavirus Disease 2019","status":"COMPLETED","sponsor":"Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital","startDate":"2020-03-22","conditions":"Covid19 and Mortality","enrollment":445},{"nctId":"NCT05100342","phase":"","title":"Prospective Validation of a Points Score System Predicting 30-day Survival","status":"RECRUITING","sponsor":"Indiana University","startDate":"2022-09-12","conditions":"Metastatic Cancer","enrollment":114},{"nctId":"NCT06330441","phase":"NA","title":"Pancreatic Cancer Screening in a Population at High Risk","status":"RECRUITING","sponsor":"Masaryk Memorial Cancer Institute","startDate":"2022-01-07","conditions":"Pancreatic Ductal Adenocarcinoma, Hereditary Diseases, Pancreatitis, Chronic","enrollment":700},{"nctId":"NCT06737380","phase":"PHASE1","title":"UC-MSC Cell Therapy Study for Systemic Lupus Erythematosus (SLE) Patients","status":"RECRUITING","sponsor":"LiveKidney.Bio","startDate":"2025-01-07","conditions":"SLE, Lupus, Systemic Lupus Erthematosus","enrollment":10},{"nctId":"NCT07089524","phase":"","title":"A Comparative Study Between Neutrophil/Lymphocyte Ratio and Lactate/Albumin Ratio as Predictive Inflammatory Markers for Sepsis","status":"RECRUITING","sponsor":"Ain Shams University","startDate":"2024-09-11","conditions":"Sepsis","enrollment":160},{"nctId":"NCT07023159","phase":"","title":"Predicting 28-Day Survival in OHCA Patients","status":"COMPLETED","sponsor":"Haseki Training and Research Hospital","startDate":"2023-05-01","conditions":"Out of Hospital Cardiac Arrest, Cardiac Arrest (CA)","enrollment":327},{"nctId":"NCT06812221","phase":"PHASE1, PHASE2","title":"Efficacy of Sublingual 5-MeO-DMT for Reducing Anxiety and Depression in MCI","status":"COMPLETED","sponsor":"Biomind Labs Inc.","startDate":"2024-12-15","conditions":"Mild Cognitive Impairment, Anxiety State, Depression Anxiety Disorder","enrollment":20},{"nctId":"NCT06816667","phase":"PHASE1, PHASE2","title":"Safety, Tolerability, and Efficacy of Sublingual Microdoses of 5-MeO-DMT for Depression and Anxiety","status":"COMPLETED","sponsor":"Biomind Labs Inc.","startDate":"2024-10-21","conditions":"Healthy Volunteers","enrollment":40},{"nctId":"NCT05435638","phase":"PHASE1","title":"Study Designed to Evaluate Safety and Efficacy of 1% Topical Formulation of KM-001 on Type 1 Punctate Palmoplantar Keratoderma or Pachyonychia Congenita Diseases","status":"COMPLETED","sponsor":"Kamari Pharma Ltd","startDate":"2022-07-17","conditions":"Punctate Palmoplantar Keratoderma Type 1, Pachyonychia Congenita","enrollment":14},{"nctId":"NCT05497830","phase":"NA","title":"Machine Learning for Risk Stratification in the Emergency Department (MARS-ED)","status":"COMPLETED","sponsor":"Maastricht University Medical Center","startDate":"2022-09-12","conditions":"Acute Pain, Emergencies","enrollment":1300},{"nctId":"NCT06586060","phase":"NA","title":"Lung Ultrasound Guided Fluid Balance Strategy in Patients with Lung Contusion","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2024-10","conditions":"Lung Contusion","enrollment":100},{"nctId":"NCT06186154","phase":"PHASE1","title":"Vitamin B12 and Folinic Acid Supplementation in Mitochondrial DNA Deletion Syndromes","status":"UNKNOWN","sponsor":"University of British Columbia","startDate":"2024-01","conditions":"Mitochondrial DNA Deletion, Macrocytosis","enrollment":25},{"nctId":"NCT04975906","phase":"","title":"The Threshold of Serum Anion Gap as a Screening Tool for Organic Acidosis","status":"COMPLETED","sponsor":"Changi General Hospital","startDate":"2017-07-01","conditions":"Metabolic Acidosis, Critical Illness, Anion Gap Acidosis","enrollment":16475},{"nctId":"NCT05535517","phase":"","title":"Development and Validation of an Investigator Global Assessment Score for Keratosis Pilaris","status":"UNKNOWN","sponsor":"Premier Specialists, Australia","startDate":"2022-08-13","conditions":"Keratosis Pilaris","enrollment":15},{"nctId":"NCT05520957","phase":"","title":"Early SARS-CoV-2 Tracheostomy","status":"COMPLETED","sponsor":"Cantonal Hospital Zenica","startDate":"2020-01-01","conditions":"Tracheostomy, Characteristics Disease, Metabolic Disturbance","enrollment":17},{"nctId":"NCT05400343","phase":"NA","title":"Efficacy of Lung and Inferior Vena Cava Sonography for Fluid Optimization","status":"UNKNOWN","sponsor":"Mansoura University","startDate":"2022-06-15","conditions":"Traumatic Brain Injury","enrollment":72},{"nctId":"NCT04308980","phase":"PHASE2, PHASE3","title":"Safety and Tolerability of Novel Medical Nutrition Products for NAFLD Treatment","status":"UNKNOWN","sponsor":"Russian Academy of Medical Sciences","startDate":"2020-03-20","conditions":"NAFLD, NASH - Nonalcoholic Steatohepatitis","enrollment":45},{"nctId":"NCT01783990","phase":"","title":"Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG) Follow-up Observational Study II Protocol","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2012-10","conditions":"Sickle Cell Anemia","enrollment":150},{"nctId":"NCT04127513","phase":"PHASE3","title":"Comparison of 12% Ammonium Lactate and 10% Urea Cream in Geriatric With Xerosis Cutis","status":"COMPLETED","sponsor":"Indonesia University","startDate":"2017-04-01","conditions":"Xerosis Cutis","enrollment":40},{"nctId":"NCT01687543","phase":"NA","title":"Probiotics for Reduction of Infections With Clostridium Difficile in Critically Ill Patients","status":"TERMINATED","sponsor":"Region Skane","startDate":"2012-06","conditions":"Clostridium Difficile Colonisation, Impact of Enteral Probiotics on Certain Lab Parameters","enrollment":25},{"nctId":"NCT02458157","phase":"PHASE4","title":"Forced Fluid Removal in High Risk Acute Kidney Injury","status":"TERMINATED","sponsor":"Nordsjaellands Hospital","startDate":"2015-10","conditions":"Acute Kidney Injury, Fluid Overload, Critical Illness","enrollment":21},{"nctId":"NCT00296036","phase":"PHASE3","title":"Pyridoxine and Topical Urea/Lactic Acid-Based Cream in Preventing Hand-Foot Syndrome in Patients Receiving Capecitabine for Breast Cancer or Other Cancer","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2006-06","conditions":"Breast Cancer, Drug/Agent Toxicity by Tissue/Organ, Unspecified Adult Solid Tumor, Protocol Specific","enrollment":137},{"nctId":"NCT00771121","phase":"PHASE4","title":"Effect of Moisturizing Creams on Skin Barrier Function","status":"UNKNOWN","sponsor":"ACO Hud Nordic AB","startDate":"","conditions":"Atopic Eczema","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":29,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"urea/lactic acid","genericName":"urea/lactic acid","companyName":"ACO Hud Nordic AB","companyId":"aco-hud-nordic-ab","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Urea and lactic acid work together to soften and exfoliate the stratum corneum while restoring skin hydration and pH balance. Used for Hyperkeratosis and xerosis (dry, thickened skin), Calluses and corns, Ichthyosis and related keratinization disorders.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}